News

Quince Therapeutics Webinar: Addressing Ataxia-Telangiectasia

Quince Therapeutics Webinar: Addressing Ataxia-Telangiectasia

Quince Therapeutics Hosts a Groundbreaking Investor Webinar

Quince Therapeutics, Inc. (Nasdaq: QNCX) is excited to announce an engaging investor webinar focusing on the urgent and unmet needs in the realm of Ataxia-Telangiectasia (A-T). This webinar is especially relevant given the increasing awareness and the critical nature of rare diseases. Led by Dr. Mary Kay Koenig, a key opinion leader from UTHealth Houston, the presentation promises insightful discussions aimed at tackling the complexities of A-T.

Current Status of Clinical Trials for A-T

In a significant update, Quince Therapeutics recently revealed that it has successfully enrolled 46 participants in its pivotal Phase 3 NEAT (Neurologic Effects of EryDex on Subjects with A-T) clinical trial. This milestone reflects the company’s commitment to exploring innovative therapeutic avenues for A-T using EryDex, an advanced treatment designed to utilize the patient's own biology.

Details of the Pivotal Phase 3 NEAT Trial

The NEAT trial is structured to recruit approximately 106 participants, primarily targeting children aged six to nine years, which includes a core group of 40 individuals for the primary analysis. The trial employs an international, multi-center randomized double-blind, placebo-controlled design, ensuring rigorous evaluation of treatment efficacy.

Insights from Quince Therapeutics Leadership

Dr. Dirk Thye, the Chief Executive Officer and Chief Medical Officer of Quince, expressed enthusiasm regarding the ongoing clinical progress. With 61 initial participants already screened, he noted that enrollment is nearing completion. The company has strategically activated new geographic regions, which is expected to expedite the screening and randomization processes significantly.

Engagement through the Investor Webinar

The investor webinar is scheduled for a morning session on a significant day, featuring in-depth discussions from Dr. Koenig. Attendees will receive a comprehensive overview of A-T, essential insights into the current landscape of therapeutic options, and updates on the much-anticipated clinical trials for EryDex.

Dr. Mary Kay Koenig’s Expertise

Dr. Mary Kay Koenig brings a wealth of knowledge in neurodegenerative disorders, having dedicated her practice to advancing research and treatment in pediatric populations. Her position at UTHealth Houston highlights her commitment to the field, making her insights invaluable for participants of the webinar.

Future Perspectives and Goals

Quince Therapeutics aims to complete full enrollment for the NEAT trial by mid-2025, with an objective to present topline results by the end of the same year. Assuming positive outcomes, they plan to submit a New Drug Application (NDA) to the FDA and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in 2026.

About EryDex and Its Clinical Promise

EryDex, an innovative formulation encapsulated in autologous red blood cells, represents Quince's flagship asset in the fight against A-T. This advanced therapy aims to provide significant neurological benefits to patients, measured against standard clinical endpoints.

About Quince Therapeutics

Quince Therapeutics is committed to pioneering treatments for rare diseases inspired by the power of patient biology. Their strategic focus on rare and challenging conditions such as A-T underscores the mission to have a meaningful impact on patients' lives.

Frequently Asked Questions

What is the focus of Quince Therapeutics' upcoming webinar?

The webinar will address the unmet needs in Ataxia-Telangiectasia (A-T) and present insights on clinical developments surrounding EryDex.

Who will be featured at the webinar?

Dr. Mary Kay Koenig, a leading expert in neurodegenerative diseases, will present, alongside Quince's CEO, Dr. Dirk Thye.

What is the NEAT clinical trial?

The NEAT trial is a pivotal Phase 3 study investigating the effectiveness of EryDex in children diagnosed with A-T.

When can we expect results from the NEAT trial?

Topline results from the NEAT trial are anticipated by the end of 2025, with further developments expected in 2026.

How can I register for the webinar?

Interested individuals can register through Quince Therapeutics' official investor relations page.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Hyundai's Revolutionary US Steel Mill Set for 2029 Rollout

Updated Category News Views 2

Hyundai's Major Steel Move: A Multibillion-Dollar Stake The steel industry scene in the U.S. just got a lot hotter with Hyundai's announcement of a $5.8 billion Electric Arc Furnace-based integrated steel mill in Louisiana. This game-changing project isn’t just a headline; it’s a concrete step towards beefing up the U.S. manufacturing backbone. Talk about...

Continue Reading
CreditRefresh's AI Tackles 1,000+ Disputes Launch Month

Updated Category News Views 3

AI-Powered Revolution in Credit Disputes Alright, here we are staring down the latest twist in the credit game. CreditRefresh, an AI-driven platform out of Dover, Delaware, has managed to kickstart its journey by challenging over 1,000 credit report errors in just its first month on the market. That's quite a sprint straight from the gate, don't you think? But hey, this...

Continue Reading
Bybit Enhances BTC Staking Yields Amid Crypto Fluctuations

Updated Category News Views 2

An Uptick in BTC Staking Yields Seems like Bybit's got a trick up their sleeve with their latest move. They've hiked BTC staking yields from a static 0.8% up to a more attractive 1.2%. Now, if you're parked with Bitcoin in this dicey market, that's a substantial 50% leap upwards. When you think about those dreamy numbers traders like me fantasize about, it’s a juicy...

Continue Reading
Orbis Celebrates 20 Years of Eye Care in Macau

Updated Category News Views 2

Celebrating Two Decades of Eye Health Innovation Orbis, a name synonymous with eye care worldwide, has hit a remarkable milestone. Celebrating two decades of commitment to eye health in Macau, they've rolled out their Flying Eye Hospital with a mission of profound impact. This isn't just about a fancy airplane; it’s about real, lasting change through training projects...

Continue Reading
IVD Study Success: Hybrid Monitoring Boosts Oversight

Updated Category News Views 1

New Strategies for IVD Clinical Studies It's high time we addressed the tangled web of managing in vitro diagnostic (IVD) clinical studies. We're talking about walking a tightrope where sponsors have to juggle regulatory scrutiny, data integrity, and operational efficiency—all while pushing innovation. Simply put, the old ways of doing things just aren't cutting it...

Continue Reading
S&P 500 Shuffle: Bloom, Illumina, Everpure Join Frenzy

Updated Category News Views 5

Index Shuffles Stir Market Pot Changes are afoot, folks, with the movers and shakers of the market indices stepping into the spotlight. A lot is brewing with S&P Dow Jones Indices making significant switches effective September 21, 2026—right before trading heats up. You better believe it's affecting more than a couple of tickers. Who's In and Who's Out? If you’ve...

Continue Reading
Sotheby's to Auction Largest Flawless Paraiba Tourmalines

Updated Category News Views 1

Jaw-Dropping Gemstones Poised for Auction Glory The art of gemology isn't just about shiny rocks; it's a concoction of beauty, rarity, and, most importantly, value. And when the world's finest stones hit the auction block, it's akin to an epic performance in a long-awaited drama. On September 17, 2026, these precious Paraiba Tourmalines, fashioned by the adept hands of...

Continue Reading
BellRing Brands Faces Legal Probe; Fiduciary Duties Questioned

Updated Category News Views 1

What's Stirring at BellRing Brands? Hey, no time like the present to dive headfirst into this mess BellRing's found itself in. On the heels of a lackluster sales forecast, just announced about a year ago, Kahn Swick & Foti's got their magnifying glasses out, searching for any shady dealings by those running the show at BellRing Brands, LLC. Why Is BellRing in the Hot...

Continue Reading
CHiQ Secures AI Award, Elevates Smart Home Living

Updated Category News Views 1

CHiQ's Big Win in the AI Game In a world where technology rarely stops spinning, CHiQ has carved its own commendable niche. Snagging the AI Home Ecosystem Brand Award at IFA 2026 in Berlin, the brand's knack for pioneering AI tech isn't just a footnote—it's the whole story. The award—enough to make your competitors green with envy—highlights how far they've come in...

Continue Reading
Vobile Teams Up with UNN for AI Factories in Brunei

Updated Category News Views 3

Delving into Vobile's Latest Strategic Move Vobile, a heavyweight in digital content protection based out of Santa Clara, California, has hit the headlines with a new venture. They've inked a strategic cooperation and commercial agreements with Unified National Networks (UNN) of Brunei Darussalam to construct AI factories. This ain't your run-of-the-mill news, folks. It's...

Continue Reading

Top 5 Most Recently Viewed Articles

NCC Group plc's Strategic Dealings and Key Information Overview

Updated Category News Views 227

Key Information on NCC Group plc's Recent Trading Activities FORM 8.5 (EPT/RI) Public Dealing Disclosure by an Exempt Principal Trader This disclosure relates to the activities of Investec Bank plc, acting in the capacity of a recognized intermediary for NCC Group plc. Important Details for Investors 1. Key Information (a) Name of exempt principal trader: Investec Bank plc

Continue Reading
CLOUDSUFI Broadens AI Reach with Mexico Expansion

Updated Category News Views 6

AI Investment Shifts to Mexico In a world racing for AI dominance, there's no snooze button for competitive advantage. CLOUDSUFI's latest move? Dropping a new AI factory in Guadalajara, Mexico. This city isn't just another notch on the map—it's a tech hub packed with engineering prowess, robust US ties, and sitting neatly in the same time zones as North America. Talk...

Continue Reading
Piedmont Lithium Sees Changes Amid Market Trends and Evaluations

Updated Category News Views 193

BMO Capital's Perspective on Piedmont Lithium's Market Standing Piedmont Lithium (NASDAQ:PLL) has drawn considerable attention from analysts, especially BMO Capital, which has retained its Market Perform rating for the stock and set a consistent price target of $8.50. This decision follows a noteworthy visit to the North American Lithium (NAL) operations, where BMO...

Continue Reading
Important Update for Holdco Nuvo Group D.G Ltd. Investors

Updated Category News Views 75

Important Update for Holdco Nuvo Group D.G Ltd. Investors Attention all stakeholders of Holdco Nuvo Group D.G Ltd. A significant update has surfaced regarding the company's equity interests. A recent court order has imposed crucial restrictions on trading activities associated with Holdco Nuvo Group D.G Ltd. This situation is important for both direct and indirect holders...

Continue Reading
Urbanfund Corp. Q2 2024 Financial Results Overview

Updated Category News Views 170

Overview of Urbanfund Corp.'s Q2 2024 Financial Results Mitchell Cohen, the Chief Executive Officer and President of Urbanfund Corp. (TSX-V: UFC), has announced the filing of the Company’s financial statements for the three and six months ending June 30, 2024. This filing includes the Consolidated Financial Statements along with the Management's Discussion and Analysis...

Continue Reading